Article
Proapoptotic Bcl-2 inhibitor as potential host directed therapy for pulmonary tuberculosis
27 Mar 2025
Abstract excerpt
Mycobacterium tuberculosis establishes within host cells by inducing anti-apoptotic Bcl-2 family proteins, triggering necrosis, inflammation, and fibrosis. Here, we demonstrate that navitoclax, an orally bioavailable, small-molecule Bcl-2 inhibitor, significantly improves pulmonary tuberculosis (TB) treatments as a host-directed therapy. Addition of navitoclax to standard TB treatments at human equipotent dosing...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
